Edition:
United Kingdom

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,426JPY
21 Nov 2017
Change (% chg)

¥0 (+0.02%)
Prev Close
¥2,426
Open
¥2,442
Day's High
¥2,463
Day's Low
¥2,422
Volume
1,926,900
Avg. Vol
2,249,155
52-wk High
¥2,730
52-wk Low
¥2,185

Select another date:

Tue, Oct 31 2017

BRIEF-Ono Pharmaceutical completes retirement of treasury shares

* Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

BRIEF- Ono Pharmaceutical completes share repurchase

* Says it completes repurchase of 15.9 million shares of its common stock, for 38.77 billion yen in total, from June 14 to Sept. 29

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

BRIEF-OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL

* Says peptide vaccine related agreement with ONO PHARMACEUTICAL CO., LTD. will close on Sept. 4

Nikkei edges down ahead of Fed; Nintendo, Ono Pharma outperform

TOKYO, June 14 Japanese stocks ended marginally lower in choppy trade on Wednesday, as investors refrained from taking positions ahead of the U.S. Federal Reserve's monetary policy decision.

BRIEF- Ono Pharmaceutical to repurchase and retire shares

* Says it will repurchase up to 20 million shares, representing 3.8 percent of outstanding

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

Select another date: